Navigation Links
uniQure Appoints Philip Astley-Sparke President US
Date:1/22/2013

AMSTERDAM, January 22, 2013 /PRNewswire/ --

uniQure B.V., the leader in the field of human gene therapy, today announced the appointment of Philip Astley-Sparke , former President and CEO of BioVex, as President US to provide strategic leadership and help build uniQure's clinical, regulatory, and commercial infrastructure in the US.

Since May 2012, Philip is a venture partner at Forbion Capital Partners, uniQure's largest investor. As a venture partner he works with selected portfolio companies to help management execute on their business plans. Philip served as Vice President and General Manager at Amgen, Inc. until December 2011, following the acquisition of BioVex, Inc. in March 2011. Philip had been President and CEO of BioVex since 2005, during which he achieved several milestones for the company: its relocation from the UK to the US, the formation of a commercial grade manufacturing facility and nascent commercial capabilities, and the successful negotiation with Amgen to acquire BioVex for up to $1bn. BioVex focused on the development of pioneering first-in-class oncolytic vaccines. Prior to BioVex, Philip was an investment banker with JP Morgan H&Q ( Robert Fleming ) where he advised on a number of high profile mergers and public financings. He qualified as a Chartered Accountant with Arthur Andersen in London and holds a Bachelor's Degree in Cellular Pathology and Molecular Pathology from Bristol University (UK).

"Philip's experience and expertise will be invaluable in building a successful US infrastructure for uniQure," says Jörn Aldag, CEO of uniQure.  "He is to devote an important part of his time to uniQure, and will become a key member of our management team. We look forward to establishing a foothold in the US, and developing uniQure to full commercial maturity."

About uniQure

uniQure is a world leader in the development of human gene based therapies. uniQure's Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency has been approved in the European Union, and is the first approved gene therapy in the Western world. uniQure's product pipeline of gene therapy products in development comprise hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene. uniQure's largest shareholders are Forbion Capital Partners and Gilde Healthcare, two of the leading life sciences venture capital firms in the Netherlands. Further information can be found at http://www.uniqure.com.


'/>"/>
SOURCE uniQure
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinsons Disease
2. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
3. Elsevier / MEDai Appoints Tom Zajac as New President
4. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
5. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
6. BioStorage Technologies Appoints New Member to Board of Directors
7. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
8. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
9. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
10. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
11. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... ... 13, 2017 , ... FireflySci Inc. started manufacturing calibration standards ... years and now they are home to a tremendous line of certified calibration ... resolution testing. , One mega advantage that FireflySci brings to the ...
(Date:7/13/2017)... ... July 13, 2017 , ... Trinity Sterile, Inc., a fast-growing ... has chosen The Copley Consulting Group to implement and deploy the Infor CloudSuite ... internal and backend operations to streamline efficiencies to meet the increasing demand for ...
(Date:7/12/2017)... ... July 11, 2017 , ... Business is booming ... intimate cooking experiences. , Over the past few weeks, Lajollacooks4u has ... cooking challenges. Founder and Chef Jodi Abel has also lead several Farmers ...
(Date:7/12/2017)... ... July 12, 2017 , ... Exact Diagnostics continues to ensure ... Vitro Diagnostic (IVD) use. Panels available include: Adenovirus, BKV, CMV, EBV, ... The Exact Diagnostics Verification Panels may be used as calibrators to establish reference points ...
Breaking Biology Technology:
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
Breaking Biology News(10 mins):